Market Outlook

Despite the number of therapy options available, metastatic HR-positive/HER2-negative breast cancer remains incurable and is a major cause of mortality and morbidity in women. Additionally, a significant need exists for therapies following hormone resistance in later lines. While the introduction of targeted therapies has helped to improve patient outcomes, a number of unmet needs and treatment gaps persist. Several emerging therapies are also poised to launch in the near term, further increasing competition in a crowded market. As this competition in HR-positive/HER2-negative breast cancer intensifies, novel therapies should more effectively address existing unmet needs to distinguish themselves from their rivals.

Questions Answered

  • What are the treatment drivers most likely to influence a therapy’s uptake for metastatic HR-positive/HER2-negative breast cancer?
  • How do current therapies perform on key drug attributes for metastatic HR-positive/HER2-negative breast cancer?
  • What are the prevailing areas of unmet need and hidden opportunities in this patient population?
  • What trade-offs are surveyed medical oncologists willing to make across different key clinical attributes and price when considering hypothetical new treatment options in metastatic HR-positive/HER2-negative breast cancer?

Product Description

Unmet Need: Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.

Markets covered: United States, France, Germany, United Kingdom.

Primary research: Survey of 60 medical oncologists in the United States and 30 medical oncologists in Europe.

Key drugs: Ibrance, letrozole, anastrozole, Faslodex, Kisqali, Verzenio, Afinitor, and exemestane.

Key metrics:

  • Stated versus derived analysis of U.S. and European physician prescribing behavior.
  • Conjoint analysis with U.S. and European physicians includes market simulator.
  • Assessment of current drug performance against treatment drivers and goals.
  • Physician perceptions of unmet need in metastatic HR-positive HER2-negative breast cancer and related diseases/subpopulations.
  • Analysis of remaining drug development opportunities.

Related Reports

Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast

The breast cancer therapy market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s...

View Details

Breast Cancer | Disease Landscape and Forecast | G7 | 2020

The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis’s Kisqali, and Eli Lilly’s Verzenio / Verze...

View Details

Breast Cancer | China In-Depth | China | 2020

Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity f...

View Details

Breast Cancer - Geographic Focus: China - Breast Cancer - China In-Depth (China)

Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity f...

View Details